138
Participants
Start Date
July 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2009
M200 (Volociximab)
7.5 mg/kg, IV infusion every week until disease progression
Liposomal Doxorubicin
40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
M200 (Volociximab)
15 mg/kg, IV infusions every week until disease progression
M200 (Volociximab)
15 mg/kg, IV infustions every other week until disease progression
Site Reference ID/Investigator# 75336, Brussels
Site Reference ID/Investigator# 75337, Antwerp
Site Reference ID/Investigator# 75338, Leuven
Site Reference ID/Investigator# 75335, Woodville South
Site Reference ID/Investigator# 75334, Toorak Gardens
Site Reference ID/Investigator# 75416, Bellinzona
Site Reference ID/Investigator# 75350, Girona
Site Reference ID/Investigator# 75354, Stockholm
Site Reference ID/Investigator# 75415, Milan
Site Reference ID/Investigator# 75333, Milan
Site Reference ID/Investigator# 75274, Baltimore
Site Reference ID/Investigator# 75297, Danville
Site Reference ID/Investigator# 75298, Williamsburg
Site Reference ID/Investigator# 75353, Madrid
Site Reference ID/Investigator# 75299, Atlanta
Site Reference ID/Investigator# 75300, Savannah
Site Reference ID/Investigator# 75296, Sunrise
Site Reference ID/Investigator# 75278, Green Bay
Site Reference ID/Investigator# 75301, Hinsdale
Site Reference ID/Investigator# 75294, Jackson
Site Reference ID/Investigator# 75279, Oklahoma City
Site Reference ID/Investigator# 75280, Dallas
Site Reference ID/Investigator# 75295, Corpus Christi
Site Reference ID/Investigator# 75275, Redondo Beach
Site Reference ID/Investigator# 75281, Anaheim
Site Reference ID/Investigator# 75346, Moscow
Site Reference ID/Investigator# 75348, Moscow
Site Reference ID/Investigator# 75347, Saint Petersburg
Site Reference ID/Investigator# 75344, Bialystok
Site Reference ID/Investigator# 75339, Krakow
Site Reference ID/Investigator# 75341, Lublin
Site Reference ID/Investigator# 75342, Poznan
Site Reference ID/Investigator# 75343, Poznan
Site Reference ID/Investigator# 75345, Szczecin
Site Reference ID/Investigator# 75340, Wroclaw
Site Reference ID/Investigator# 75349, Barcelona
Site Reference ID/Investigator# 75351, Barcelona
Site Reference ID/Investigator# 75352, Barcelona
Site Reference ID/Investigator# 75355, Umeå
Collaborators (1)
Biogen
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY